Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

NGL Fine-Chem Ltd Stock Analysis

Small Cap
Evaluated by 549 users | BSE: 524774 | NSE: |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 14.05%7.46%12.78%16.47%18.51%23.88%21.1%14.06%18.07%9.74%37.16%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 35.436.155.678.988.396.399.7114153152258299
Y-o-Y Gr. Rt.-2.1%53.9%41.9%12%9%3.6%14%34.8%-0.7%69.7%-
Adjusted EPS (Rs.) 3.91.694.738.1411.3118.4522.9218.592916.6388.13105.79
Y-o-Y Gr. Rt.--56.7%179.9%72.1%38.9%63.1%24.2%-18.9%56%-42.7%430%-
Book Value per Share (Rs.) 25.9927.6932.439.7353.1271.5796.16116.61149.11163.81251.62303.87
Adjusted Net Profit 2.41.12.95711.414.211.517.910.354.565
Net Op. Cash Flow (Rs. Cr.) 4.31.40-0.37.58.49.922.48.919.626.6-
Debt to Cash Flow from Ops 1.467.29-567.82-56.21.761.722.31.193.071.440.62-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
NGL Fine-Chem Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 24.4%21.8%31.5%69.7%
Adjusted EPS 55.2%36.7%68%430%
Book Value per Share 27.828.629.253.6
Share Price 68.6% 53% 79.8% 113.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 16.236.3115.7322.5824.3729.5927.3317.4721.8210.6342.4338.09
Operating Profit Margin (%) 15.0110.9113.6214.2616.9322.825.5518.9721.0815.2129.8427.53
Net Profit Margin (%) 6.812.95.256.387.9111.8414.210.111.76.7521.0921.87
Debt to Equity 0.390.60.670.680.40.330.380.370.290.280.110.02
Working Capital Days 162184147138152160187198167191137192
Cash Conversion Cycle 6576596265748165557949114
Loading price chart...
Entity Percentage Holding
Promoters 73.81%
Non-Institutions 26.19%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

NGL Fine-Chem Ltd's earnings have grown by 36.7%, whereas share price has appreciated 53% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

NGL Fine-Chem Ltd share price has appreciated 68.6% annually (CAGR) over the past ten years.

Data is not available for this company.

NGL Fine-chem  is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.

Its business is modelled around the changing customer demands and their ability to offer value-added innovative solutions to meet and even exceed these demands.

Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand

NGL Fine-chem  is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.

Its business is modelled around the changing customer demands and their ability to offer value-added innovative solutions to meet and even exceed these demands.

Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand the product portfolio with new products.

It has established a strong presence in global pharmaceutical companies with its commitment to competitive prices, delivery schedules, international quality standards and constant technological upgradation.

NGL Fine-chem Ltd has a strong focus on developing intellectual property as a key differentiator and as a platform for further growth up the pharma value chain. It respect intellectual property and invest in developing it as a key growth driver for the future.

Product range of the company includes:

Pharmaceutical like Diminazene Aceturate, Diminazene Diaceturate, Homidium Chloride, Nitroxynil, Clorsulon, Homidium Bromide, Parvaquone, Carprofen, Buparvaquone and Isometamidium Chloride Hydrochloride for:

  • Animal health
  • Human health
  • Intermediate- 4 Aminobenzamidine Dihydrochloride, 3 Aminobenzamidine Dihydrochloride, Ezetimibe Intermediates etc
  • Finished dosages form- Homidium Chloride Tablets, Diminazene Aceturate Granules

Achievements/ recognition

An ISO 9001:2000 accredited company

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback